Other current therapy areas

A Chinese cohort study identifies factors associated with prognosis among patients with connective tissue disease-associated pulmonary arterial hypertension.

Study results suggest that right atrial strain could predict adverse outcomes among patients with pulmonary arterial hypertension.

Evaluation of pulmonary arterial compliance after initiation or escalation of therapy for pulmonary arterial hypertension more accurately predicts prognosis than conventional right heart hemodynamic parameters, Italian study findings indicate.

Among patients with hepatitis B virus-related decompensated cirrhosis, first-line tenofovir disoproxil fumarate therapy not only reduces HBV DNA levels, but also improves hepatic function, indicates a real-world South Korean study.

The infant recombinant yeast hepatitis B virus vaccine has long-term efficacy, but the rate of disappearance of protective antibodies against hepatitis B surface antigen is higher than with the plasma-derived vaccine, shows a study of Taiwanese university students.

Korean researchers show that the PAGE-B model for prediction of hepatocellular carcinoma risk has applicability in Asian patients with chronic hepatitis B virus infection treated with entecavir or tenofovir disoproxil fumarate.

Researchers have devised a new measure for assessing the effect of asthma on quality of life from the patient’s perspective.

Study findings show a high prevalence of poorly controlled asthma among patients treated with inhaled corticosteroid and long-acting beta-agonist combination therapy, highlighting poor treatment adherence or an unmet need in current treatment.

Suppression of type 2 innate lymphoid cells by activated plasmacytoid dendritic cells could present a regulatory pathway for pulmonary inflammation, early research suggests.

High neutrophil counts, leflunomide treatment, and the absence of anti-citrullinated protein antibodies are associated with increased risk for serious infection among patients with rheumatoid arthritis who are treated with tocilizumab, researchers report.

Patients with rheumatoid arthritis who stop tumor necrosis factor inhibitor therapy experience worse patient-reported outcomes in the short-term than those who continue treatment, analysis of trial data suggests.

Initiation of statin treatment is associated with a “substantially lower risk” for mortality among patients with ankylosing spondylitis, researchers report.